Key points from article :
Cambrian Biopharma announced the close of an oversubscribed Series C financing, which raised $100 million.
The financing was co-led by Anthos Capital and SALT Fund.
To combat the biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan.
James Peyer, CEO and Co-Founder of Cambrian says "....partner with more scientific innovators to bring more programs under the Cambrian banner.”
Age-related diseases account for more than two-thirds of all deaths worldwide.
Cambrian’s pipeline targets a different type of damage that builds up with age.
Tested for clinical safety and efficacy in an acute indication.
Unique drug discovery model combines the advantages of a venture capital firm and a big pharmaceutical company.
Christian Angermayer, Cambrian’s Co-Founder and Chairman says "...challenging us to think about today’s most deadly diseases in a new way.”
It has 14 novel therapeutics in development across its majority-held pipeline companies.
